Hypoloc Comp 5 mg / 12,5 mg tabletti, kalvopäällysteinen Soome - soome - Fimea (Suomen lääkevirasto)

hypoloc comp 5 mg / 12,5 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - nebivolol hydrochloride, hydrochlorothiazide - tabletti, kalvopäällysteinen - 5 mg / 12,5 mg - nebivololi ja tiatsidit

Hypoloc 5 mg tabletti Soome - soome - Fimea (Suomen lääkevirasto)

hypoloc 5 mg tabletti

menarini international operations luxembourg s.a. - nebivolol hydrochloride - tabletti - 5 mg - nebivololi

BENETOR COMP 40 mg / 12.5 mg tabletti, kalvopäällysteinen Soome - soome - Fimea (Suomen lääkevirasto)

benetor comp 40 mg / 12.5 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - olmesartani medoxomilas,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 40 mg / 12.5 mg - olmesartaanimedoksomiili ja diureetit

BENETOR COMP 40 mg / 25 mg tabletti, kalvopäällysteinen Soome - soome - Fimea (Suomen lääkevirasto)

benetor comp 40 mg / 25 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - olmesartani medoxomilas,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 40 mg / 25 mg - olmesartaanimedoksomiili ja diureetit

Skudexa 75 mg / 25 mg tabletti, kalvopäällysteinen Soome - soome - Fimea (Suomen lääkevirasto)

skudexa 75 mg / 25 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - tramadol hydrochloride, dexketoprofen trometamol - tabletti, kalvopäällysteinen - 75 mg / 25 mg - tramadoli ja deksketoprofeeni

Skudexa 75 mg / 25 mg rakeet oraaliliuosta varten, annospussi Soome - soome - Fimea (Suomen lääkevirasto)

skudexa 75 mg / 25 mg rakeet oraaliliuosta varten, annospussi

menarini international operations luxembourg s.a. - tramadol hydrochloride, dexketoprofen trometamol - rakeet oraaliliuosta varten, annospussi - 75 mg / 25 mg - tramadoli ja deksketoprofeeni

Quofenix Euroopa Liit - soome - EMA (European Medicines Agency)

quofenix

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumiini - yhteisön hankkimat infektiot - systeemiset bakteerilääkkeet, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Elzonris Euroopa Liit - soome - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiset aineet - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Invokana Euroopa Liit - soome - EMA (European Medicines Agency)

invokana

janssen-cilag international nv - canagliflozin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5.

Nucala Euroopa Liit - soome - EMA (European Medicines Agency)

nucala

glaxosmithkline trading services - mepolizumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.